Fostamatinib Disodium Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as RIGEL PHARMS. It is marketed under 1 brand name, including TAVALISSE. Available in 2 different strengths, such as EQ 100MG BASE, EQ 150MG BASE, and administered through 1 route including TABLET;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"100387","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"3526d014bc65480b9108","publication_number":"US9266912B2","cleaned_patent_number":"9266912","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-01-19","publication_date":"2016-02-23","legal_status":"Granted"} US9266912B2 23 Feb, 2016 Granted 19 Jan, 2026
{"application_id":"100384","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"3526d014bc65480b9108","publication_number":"US8211889B2","cleaned_patent_number":"8211889","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-01-19","publication_date":"2012-07-03","legal_status":"Granted"} US8211889B2 Molecular 03 Jul, 2012 Granted 19 Jan, 2026
{"application_id":"100344","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"76bd6f267e6c4317a47b","publication_number":"USRE48898E","cleaned_patent_number":"RE48898","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-01-19","publication_date":"2022-01-25","legal_status":"Granted"} USRE48898E1 Formulation 25 Jan, 2022 Granted 19 Jan, 2026
{"application_id":"100381","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"3526d014bc65480b9108","publication_number":"US7538108B2","cleaned_patent_number":"7538108","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-03-28","publication_date":"2009-05-26","legal_status":"Granted"} US7538108B2 Molecular 26 May, 2009 Granted 28 Mar, 2026
{"application_id":"100349","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"3526d014bc65480b9108","publication_number":"US7989448B2","cleaned_patent_number":"7989448","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-06-12","publication_date":"2011-08-02","legal_status":"Granted"} US7989448B2 Molecular 02 Aug, 2011 Granted 12 Jun, 2026
{"application_id":"100340","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"76bd6f267e6c4317a47b","publication_number":"US8163902B2","cleaned_patent_number":"8163902","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-06-17","publication_date":"2012-04-24","legal_status":"Granted"} US8163902B2 Molecular 24 Apr, 2012 Granted 17 Jun, 2026
{"application_id":"100331","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"76bd6f267e6c4317a47b","publication_number":"US9283238B2","cleaned_patent_number":"9283238","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-06-17","publication_date":"2016-03-15","legal_status":"Patented case"} US9283238B2 15 Mar, 2016 Patented case 17 Jun, 2026
{"application_id":"100342","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"76bd6f267e6c4317a47b","publication_number":"US8912170B2","cleaned_patent_number":"8912170","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-06-17","publication_date":"2014-12-16","legal_status":"Granted"} US8912170B2 16 Dec, 2014 Granted 17 Jun, 2026
{"application_id":"100341","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"76bd6f267e6c4317a47b","publication_number":"US8445485B2","cleaned_patent_number":"8445485","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-06-17","publication_date":"2013-05-21","legal_status":"Granted"} US8445485B2 Formulation 21 May, 2013 Granted 17 Jun, 2026
{"application_id":"100458","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"804cb16bb79944639cbf","publication_number":"US8652492B2","cleaned_patent_number":"8652492","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-11-06","publication_date":"2014-02-18","legal_status":"Granted"} US8652492B2 Formulation 18 Feb, 2014 Granted 06 Nov, 2028
{"application_id":"100424","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"804cb16bb79944639cbf","publication_number":"US8263122B2","cleaned_patent_number":"8263122","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-11-24","publication_date":"2012-09-11","legal_status":"Granted"} US8263122B2 Formulation 11 Sep, 2012 Granted 24 Nov, 2030
{"application_id":"100380","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"3526d014bc65480b9108","publication_number":"US7449458B2","cleaned_patent_number":"7449458","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-04","publication_date":"2008-11-11","legal_status":"Granted"} US7449458B2 Molecular 11 Nov, 2008 Granted 04 Sep, 2031
{"application_id":"100396","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"3bc1cd08e2da479294e9","publication_number":"US8951504B2","cleaned_patent_number":"8951504","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-07-27","publication_date":"2015-02-10","legal_status":"Granted"} US8951504B2 10 Feb, 2015 Granted 27 Jul, 2032
{"application_id":"100420","ingredient":"FOSTAMATINIB DISODIUM","trade_name":"TAVALISSE","family_id":"3bc1cd08e2da479294e9","publication_number":"US8771648B2","cleaned_patent_number":"8771648","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-07-27","publication_date":"2014-07-08","legal_status":"Granted"} US8771648B2 Formulation 08 Jul, 2014 Granted 27 Jul, 2032

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Fostamatinib Disodium

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.